Nuvectis Pharma (NVCT)
(Real Time Quote from BATS)
$6.50 USD
+0.20 (3.18%)
Updated Aug 13, 2024 10:30 AM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Nuvectis Pharma, Inc. [NVCT]
Reports for Purchase
Showing records 21 - 40 ( 68 total )
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q23: NXP800 In Phase 1b, NXP900 Phase 1 Start-Up Next, Funded Into 2H24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Pair of Oncology Assets Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Cholangiocarcinoma Models Show NXP800 Efficacy At AACR
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
First in Human Study of NXP800 Advances Into Phase 1b in Defined Ovarian Cancer Population
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
NXP800 Phase 1b Starts In Pt- Resistant, ARID1a-Mutated Ovarian Carcinoma
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: NXP800 Soon to Start Phase 1b, NXP900 Phase 1 to Start by Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Therapeutic Tag Team; NXP800 Phase 1a Nears Completion as NXP900 Readies for Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preclinical Data for NXP800 at 2023 ESMO Gynocological Meeting
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Mouse Model of NXP900 Efficacy in Xtandi-Resistant mCRPC Published
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Study Places Nice Focus on NXP-900
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Using ENGOT & GOG for NXP800 Phase 1b Trial in ARID1A-Mutated Cancers
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
NXP800 Global Clinical Development Outlook Strengthens With Leading Consortia Collaboration
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Well Funded to Advance NXP800 And NXP900, Phase 1a Data 4Q22/1Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J